323 related articles for article (PubMed ID: 31447000)
21. CK-19 mRNA-positive cells in peripheral blood predict treatment efficacy and survival in small-cell lung cancer patients.
Shi WL; Li J; Du YJ; Zhu WF; Wu Y; Hu YM; Chen YC
Med Oncol; 2013 Dec; 30(4):755. PubMed ID: 24178178
[TBL] [Abstract][Full Text] [Related]
22. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
[TBL] [Abstract][Full Text] [Related]
23. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
[TBL] [Abstract][Full Text] [Related]
24. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
25. Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients.
Krawczyk N; Neubacher M; Meier-Stiegen F; Neubauer H; Niederacher D; Ruckhäberle E; Mohrmann S; Hoffmann J; Kaleta T; Banys-Paluchowski M; Reinecke P; Esposito I; Janni W; Fehm T
BMC Cancer; 2019 Nov; 19(1):1101. PubMed ID: 31718606
[TBL] [Abstract][Full Text] [Related]
26. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.
Xu L; Mao X; Imrali A; Syed F; Mutsvangwa K; Berney D; Cathcart P; Hines J; Shamash J; Lu YJ
PLoS One; 2015; 10(9):e0138032. PubMed ID: 26397728
[TBL] [Abstract][Full Text] [Related]
27. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
Sharma SK; Pourat J; Abdel-Atti D; Carlin SD; Piersigilli A; Bankovich AJ; Gardner EE; Hamdy O; Isse K; Bheddah S; Sandoval J; Cunanan KM; Johansen EB; Allaj V; Sisodiya V; Liu D; Zeglis BM; Rudin CM; Dylla SJ; Poirier JT; Lewis JS
Cancer Res; 2017 Jul; 77(14):3931-3941. PubMed ID: 28487384
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.
Milaki G; Messaritakis I; Koinis F; Kotsakis A; Apostolaki S; Dermitzaki EK; Perraki M; Hatzidaki D; Georgoulias V
Cancer Chemother Pharmacol; 2017 Jul; 80(1):101-108. PubMed ID: 28523597
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
Tanaka K; Isse K; Fujihira T; Takenoyama M; Saunders L; Bheddah S; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Jan; 115():116-120. PubMed ID: 29290251
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis.
Zhu HH; Liu YT; Feng Y; Zhang LN; Zhang TM; Dong GL; Xing PY; Wang HY; Shi YK; Hu XS
Thorac Cancer; 2021 Oct; 12(20):2749-2757. PubMed ID: 34423906
[TBL] [Abstract][Full Text] [Related]
31. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
[TBL] [Abstract][Full Text] [Related]
32. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
[TBL] [Abstract][Full Text] [Related]
33. High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1.
Schehr JL; Schultz ZD; Warrick JW; Guckenberger DJ; Pezzi HM; Sperger JM; Heninger E; Saeed A; Leal T; Mattox K; Traynor AM; Campbell TC; Berry SM; Beebe DJ; Lang JM
PLoS One; 2016; 11(7):e0159397. PubMed ID: 27459545
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP
Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387
[TBL] [Abstract][Full Text] [Related]
35. Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
Papadaki MA; Messaritakis I; Fiste O; Souglakos J; Politaki E; Kotsakis A; Georgoulias V; Mavroudis D; Agelaki S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477700
[TBL] [Abstract][Full Text] [Related]
36. Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer.
Beck TN; Boumber YA; Aggarwal C; Pei J; Thrash-Bingham C; Fittipaldi P; Vlasenkova R; Rao C; Borghaei H; Cristofanilli M; Mehra R; Serebriiskii I; Alpaugh RK
BMC Cancer; 2019 Jun; 19(1):603. PubMed ID: 31215484
[TBL] [Abstract][Full Text] [Related]
37. TREM1/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer.
Nie F; Chen Y; Hu Y; Huang P; Shi X; Cai J; Qiu M; Wang E; Lu K; Sun M
Immunology; 2024 Jul; 172(3):362-374. PubMed ID: 38469682
[TBL] [Abstract][Full Text] [Related]
38. Rovalpituzumab tesirine resistance: analysis of a corresponding small cell lung cancer and circulating tumor cell line pair.
Rath B; Plangger A; Krenbek D; Hochmair M; Stickler S; Tretter V; Hamilton G
Anticancer Drugs; 2022 Mar; 33(3):300-307. PubMed ID: 34924498
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.
Hou JM; Krebs MG; Lancashire L; Sloane R; Backen A; Swain RK; Priest LJ; Greystoke A; Zhou C; Morris K; Ward T; Blackhall FH; Dive C
J Clin Oncol; 2012 Feb; 30(5):525-32. PubMed ID: 22253462
[TBL] [Abstract][Full Text] [Related]
40. The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy.
Tendler S; Kanter L; Lewensohn R; Ortiz-Villalón C; Viktorsson K; De Petris L
PLoS One; 2020; 15(10):e0240973. PubMed ID: 33104707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
